Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML
(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...
A recent clinical trial conducted by the Children's Oncology Group indicates that a liposomal daunorubicin and cytarabine combination is not superior to the standard induction therapy in pediatric acute myeloid leukemia (AML) patients. The research, led by Todd Cooper, DO, of Seattle Children's Hospital, compared the outcomes of patients treated with either the standard or liposomal treatment.
The study found that the 2-year event-free survival rate was lower in the liposomal group for low-risk AML patients (57.5% vs 73.8%, P=0.001), suggesting the combination may not be optimal for this patient group.
Written by urgent.news from MedPage Today's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
